Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.97 - $3.08 $16,876 - $53,585
-17,398 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.55 - $5.23 $4,901 - $10,052
-1,922 Reduced 9.95%
17,398 $50,000
Q4 2021

Feb 11, 2022

BUY
$4.43 - $8.33 $4,217 - $7,930
952 Added 5.18%
19,320 $85,000
Q3 2021

Nov 04, 2021

SELL
$6.07 - $9.89 $3,338 - $5,439
-550 Reduced 2.91%
18,368 $133,000
Q2 2021

Aug 11, 2021

BUY
$9.76 - $14.15 $41,763 - $60,547
4,279 Added 29.23%
18,918 $185,000
Q1 2021

May 13, 2021

SELL
$7.66 - $13.38 $9,628 - $16,818
-1,257 Reduced 7.91%
14,639 $173,000
Q4 2020

Feb 16, 2021

BUY
$6.1 - $7.94 $26,608 - $34,634
4,362 Added 37.82%
15,896 $125,000
Q3 2020

Nov 12, 2020

BUY
$6.52 - $8.94 $16,821 - $23,065
2,580 Added 28.81%
11,534 $79,000
Q2 2020

Aug 13, 2020

BUY
$6.18 - $10.76 $9,863 - $17,172
1,596 Added 21.69%
8,954 $68,000
Q1 2020

May 14, 2020

BUY
$6.03 - $15.24 $2,014 - $5,090
334 Added 4.76%
7,358 $46,000
Q4 2019

Feb 14, 2020

BUY
$9.07 - $15.84 $14,203 - $24,805
1,566 Added 28.69%
7,024 $105,000
Q3 2019

Nov 14, 2019

SELL
$9.63 - $14.0 $4,372 - $6,356
-454 Reduced 7.68%
5,458 $55,000
Q2 2019

Aug 14, 2019

SELL
$13.4 - $17.67 $138,877 - $183,131
-10,364 Reduced 63.68%
5,912 $87,000
Q1 2019

May 15, 2019

BUY
$5.7 - $19.7 $81,658 - $282,222
14,326 Added 734.67%
16,276 $266,000
Q4 2018

Feb 14, 2019

SELL
$5.57 - $11.65 $40,065 - $83,798
-7,193 Reduced 78.67%
1,950 $10,000
Q3 2018

Dec 21, 2021

BUY
$11.32 - $15.7 $12,067 - $16,736
1,066 Added 13.2%
9,143 $110,000
Q3 2018

Nov 14, 2018

SELL
$11.32 - $15.7 $134,968 - $187,191
-11,923 Reduced 59.61%
8,077 $96,000
Q2 2018

Aug 14, 2018

BUY
$13.5 - $14.52 $270,000 - $290,400
20,000 New
20,000 $270,000

Others Institutions Holding MGTA

About Magenta Therapeutics, Inc.


  • Ticker MGTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,890,500
  • Description
  • Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...
More about MGTA
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.